Nora Pharma has received approval for its first Biosimilar product.
Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG (a pegylated form of filgrastim) in Canada.
“With this product, we demonstrate to the Canadian market our determination to be a leader in the pharmaceutical sector,” said Malek Chamoun, President of Nora Pharma.
“This is an important milestone for our mission of bringing high-quality affordable medicines to patients across Canada,” he added.
NIOPEG is a Biosimilar comparable to the reference biologic drug NEULASTA (pegfilgrastim). NIOPEG is a long-acting form of recombinant human granulocyte colony-stimulating factor (r-HuG-CSF), or filgrastim. It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. NIOPEG is available in a pre-filled syringe of 6 mg/0.6 mL.
“NIOPEG is used to help prevent infection in people with non-myeloid cancers who are receiving chemotherapy. An example of a non-myeloid cancer is breast cancer,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “Biosimilars will have a significant impact on the sustainability of drug insurance plans, ensuring patient access to these high-quality treatments for years to come,” he continued.
Nora Pharma is a Canadian pharmaceutical company offering generic and specialty drugs across the country. Nora Pharma is positioned as a partner of choice in optimizing the service offering to pharmacy partners and providing patients with access to affordable, high-quality pharmaceutical products.